Development of an attenuated interleukin‐2 fusion protein that can be activated by tumour‐expressed proteases

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Immunology

• Publication date

  2011-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1365-2567.2011.03428.xPMID 21426339PMCID PMC3088983
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

  2011cited by this paper
• Cancer immunology.

  2011cited by this paper
• A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer

  2010cited by this paper
• New therapies for castration-resistant prostate cancer.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Omental immune aggregates and tumor metastasis within the peritoneal cavity

  2009cited by this paper
• Myeloid-derived suppressor cells as regulators of the immune system

  2009cited by this paper
• Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1

  2009cited by this paper
• Clinical decisions. Management of prostate cancer.

  2008cited by this paper
• Cancer Immunology

  2008cited by this paper
• Regulatory T cells and treatment of cancer.

  2008cited by this paper
• The biology of interleukin-2.

  2008cited by this paper
• Local therapy of cancer with free IL-2

  2008cited by this paper
• Adoptive cell transfer: a clinical path to effective cancer immunotherapy

  2008cited by this paper
• Immunosuppressive strategies that are mediated by tumor cells.

  2007cited by this paper
• Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.

  2007cited by this paper
• Interleukin 2: from immunostimulation to immunoregulation and back again

  2007cited by this paper
• Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1

  2007cited by this paper
• Human T cell responses against melanoma.

  2006cited by this paper
• Immunity to melanoma antigens: from self-tolerance to immunotherapy.

  2006cited by this paper
• The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs

  2006cited by this paper
• Antibody targeted drugs as cancer therapeutics

  2006cited by this paper
• Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes.

  2006cited by this paper
• Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease

  2006cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006cited by this paper
• Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma

  2005cited by this paper
• Modification of MTT assay conditions to examine the cytotoxic effects of amitraz on the human lymphoblastoid cell line, WIL2NS.

  2005cited by this paper
• Immunosuppressive networks in the tumour environment and their therapeutic relevance

  2005cited by this paper
• High Serum Levels of Matrix Metalloproteinase-9 and Matrix Metalloproteinase-1 Are Associated with Rapid Progression in Patients with Metastatic Melanoma

  2005cited by this paper
• Optimization of codon pair use within the (GGGGS)3 linker sequence results in enhanced protein expression.

  2004cited by this paper
• Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

  2004cited by this paper
• Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

  2004cited by this paper
• Antibody-cytokine fusion proteins: innovative weapons in the war against cancer

  2004cited by this paper
• Targeting cytokines to inflammation sites

  2003cited by this paper
• Biology of prostate-specific antigen.

  2003cited by this paper
• Biology of prostate-specific antigen.

  2003cited by this paper
• Interleukin-12 and the regulation of innate resistance and adaptive immunity

  2003cited by this paper
• A Unique Substrate Recognition Profile for Matrix Metalloproteinase-2*

  2002cited by this paper
• New functions for the matrix metalloproteinases in cancer progression

  2002cited by this paper
• Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2‐expressing tumors

  2002cited by this paper
• Controlled Local Delivery of Interleukin-2 by Biodegradable Polymers Protects Animals from Experimental Brain Tumors and Liver Tumors

  2001cited by this paper
• Recombinant human antibody single chain variable fragments reactive with Candida albicans surface antigens.

  2001cited by this paper
• Progress in human tumour immunology and immunotherapy

  2001cited by this paper
• T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes.

  2001cited by this paper
• In vivo molecular target assessment of matrix metalloproteinase inhibition

  2001cited by this paper
• Matrix metalloproteinases in human melanoma.

  2000cited by this paper
• In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity.

  2000cited by this paper
• Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

  2000cited by this paper
• Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

  1999cited by this paper
• Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.

  1999cited by this paper
• Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity

  1998cited by this paper
• Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.

  1997cited by this paper
• Changing views of the role of matrix metalloproteinases in metastasis.

  1997cited by this paper
• Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.

  1997cited by this paper
• Soluble cytokine receptors.

  1996cited by this paper
• Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy.

  1996cited by this paper
• Analysis of antibody selection by phage display utilizing anti‐phenobarbital antibodies

  1996cited by this paper
• Synergistic effects of co‐expression of the Th1 cytokines il‐2 and IFNγ on generation of murine tumor‐reactive cytotoxic cells

  1995cited by this paper
• Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model.

  1995cited by this paper
• Paracrine cytokine adjuvants in cancer immunotherapy.

  1995cited by this paper
• Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor.

  1995cited by this paper
• Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles.

  1994cited by this paper
• Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

  1994cited by this paper
• Immunizing and Curative Potential of Replicating and Nonreplicating Murine Mammary Adenocarcinoma Cells Engineered with Interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, Tumor Necrosis Factor α, Granulocyte-Macrophage Colony-stimulating Factor, and γ-Interferon Gene or Admixed with Conventional Adjuvants

  1994cited by this paper
• Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional a

  1994cited by this paper
• Morpho-physiological function and role of omental milky spots as omentum-associated lymphoid tissue (OALT) in the peritoneal cavity.

  1993cited by this paper
• Isolation and expansion of tumor-infiltrating lymphocytes.

  1993cited by this paper
• Anti‐metastatic vaccination of tumor‐bearing mice with il‐2‐gene‐inserted tumor cells

  1993cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• The IL-2 receptor complex: its structure, function, and target genes.

  1993cited by this paper
• Inhibition of tumor growth by histoincompatible cells expressing interleukin-2.

  1992cited by this paper
• Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

  1990cited by this paper
• Expression of the full-length products of the human papillomavirus type 6b (HPV-6b) and HPV-11 L2 open reading frames by recombinant baculovirus, and antigenic comparisons with HPV-11 whole virus particles.

  1990cited by this paper
• Biology of interleukin-2

  1984cited by this paper
• Assessment of in situ host immunity to syngeneic tumors utilizing the multicellular spheroid model.

  1984cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• Tumorigenesis and Neoplastic Progression Preferential Attachment of Peritoneal Tumor Metastases to Omental Immune Aggregates and Possible Role of a Unique Vascular Microenvironment in Metastatic Survival and Growth

  year unknowncited by this paper

• Harnessing cytokine immunocomplexes and cytokine fusion proteins for cancer Therapy: Mechanisms and clinical potential.

  2025cites this paper
• Redirecting immune signaling with cytokine adaptors

  2025cites this paper
• Orthogonalized human protease control of secreted signals

  2025cites this paper
• Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives

  2025cites this paper
• Emerging trends and therapeutic applications of monoclonal antibodies.

  2024cites this paper
• Orthogonalized human protease control of secreted signals

  2024cites this paper
• Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy.

  2024cites this paper
• Cytokines in cancer.

  2024cites this paper
• Synaptic synergy of T cell receptor and interleukin 2 receptor in CD8+ T cells

  2024cites this paper
• Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview

  2024cites this paper
• Innate Immunity in Cancer Biology and Therapy

  2023cites this paper
• BRAIDing receptors for cell-specific targeting

  2023cites this paper
• Strategies for Conditional Regulation of Proteins

  2023cites this paper
• Massively parallel, computationally guided design of a proenzyme

  2022cites this paper
• A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy

  2022cites this paper
• A Protease Activatable Interleukin-2 Fusion Protein Engenders Antitumor Immune Responses by Interferon Gamma-Dependent and Interferon Gamma-Independent Mechanisms

  2022cites this paper
• Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker

  2022cites this paper
• Exploiting protease activation for therapy

  2022cites this paper
• Role of Serine Proteases at the Tumor-Stroma Interface

  2022cites this paper
• A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors

  2022cites this paper
• Next-generation cytokines for cancer immunotherapy

  2021cites this paper
• Molecular and Macroscopic Therapeutic Systems for Cytokine‐Based Cancer Immunotherapy

  2021cites this paper
• Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity

  2021cites this paper
• Significant and Conflicting Correlation of IL-9 With Prevotella and Bacteroides in Human Colorectal Cancer

  2020cites this paper
• ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

  2020cites this paper
• A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating 1 lymphocytes for potent antitumor therapy

  2020cites this paper
• Development of oncolytic virotherapy: from genetic modification to combination therapy

  2020cites this paper
• A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy

  2020cites this paper
• Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9

  2019cites this paper
• Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2

  2018cites this paper
• A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss

  2018cites this paper
• The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer

  2018cites this paper
• IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells

  2018cites this paper
• Delivering safer immunotherapies for cancer

  2017cites this paper
• Engineering carboxypeptidase G2 circular permutations for the design of an autoinhibited enzyme

  2017cites this paper
• Animal models of colorectal peritoneal metastasis

  2016cites this paper
• Role of IL-2 in cancer immunotherapy

  2016cites this paper
• Characterization of an IL-12 p40/p35 Truncated Fusion Protein That Can Inhibit the Action of IL-12

  2015cites this paper
• Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: Association with asymptomatic inflammatory prostatitis NIH category IV

  2015cites this paper
• Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy

  2014cites this paper
• Generation of a dual-functioning antitumor immune response in the peritoneal cavity.

  2013cites this paper
• Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo

  2013cites this paper
• IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor.

  2013cites this paper
• Local expression of interleukin‐2 by B16 melanoma cells results in decreased tumour growth and long‐term tumour dormancy

  2013cites this paper